Anti-Vascular Endothelial Growth Factor and the Evolving Management Paradigm for Retinopathy of Prematurity

Area of Science:

• Ophthalmology
• Pediatric Retinal Diseases
• Medical Technology

Background:

• Pediatric retinal conditions, including retinopathy of prematurity (ROP), require evolving diagnostic and management approaches.
• Advancements in imaging, telemedicine, and pharmacotherapy are significantly impacting care delivery for children with retinal diseases.

Purpose of the Study:

• To provide an updated review of current diagnostic and therapeutic modalities for pediatric retinal vascular diseases.
• To focus on the evolving role of anti-vascular endothelial growth factor (VEGF) therapy in managing retinopathy of prematurity (ROP).

Main Methods:

• Review of current literature on diagnostic tools like fluorescein angiography and optical coherence tomography.
• Analysis of emerging treatment options, particularly intravitreal anti-VEGF pharmacotherapy for ROP.
• Discussion of telemedicine and tele-education's role in overcoming access challenges in pediatric eye care.

Main Results:

• New imaging systems and telemedicine enhance the diagnosis and accessibility of care for pediatric retinal diseases.
• Anti-VEGF therapy represents a significant advancement in treatment, though safety and optimal use in pediatric populations require further investigation.
• Ongoing studies are crucial for determining optimal dosing, systemic safety, and recurrence patterns of anti-VEGF treatment for ROP.

Conclusions:

• Technological innovations and anti-VEGF therapy are revolutionizing the diagnosis and management of pediatric retinal diseases like ROP.
• Further research is essential to fully understand the long-term safety and efficacy of anti-VEGF agents in pediatric patients.
• Telemedicine and advanced imaging hold promise for improving care access and quality for children with retinal conditions.